# List of investigational obsessive–compulsive disorder drugs

This is a list of investigational obsessive–compulsive disorder drugs, or drugs that are currently under development for clinical use in the treatment of obsessive–compulsive disorder (OCD) but are not yet approved.
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in September 2021. It is likely to become outdated with time.

## Under development
### Actively under development

* Immunoglobulin (immune globulin 10%, 10% high purity immunoglobulin, 10% IVIG, NewGam, Newnorm, Octagam 10%, Octagam, Panzyga) – immunoglobulin / immunostimulant
* Troriluzole (BHV-4157, BHV-4157a, FC-4157; trigriluzole) – prodrug of riluzole / glutamate modulator

### Preclinical development

* Cannabis extracts (various) – cannabinoid receptor modulators

### No development reported

* 4'-Fluorocannabidiol (4'-F-CBD; fluorinated cannabidiol; HUF-101, HUF-102, HUF-103) – cannabinoid receptor modulator, other actions
* AbbVie/Rugen research programme – unspecified mechanism of action
* Agomelatine (Alodil, Melitor, Thymanax, Valdoxan, Vestin; AGO-178, AGO178C, S-20098, S-20098-F55) – serotonin 5-HT$_{2C}$ receptor antagonist and melatonin receptor agonist
* CR-5542 – orexin receptor antagonist
* Dual SSRIs and serotonin 5-HT$_{1A}$ receptor agonists (SSA-426, WAY-163426, WAY-211612, WAY-253752, WAY-426)
* Risperidone (Risperdal, Risperdal Consta, Risperdal Depot; JNJ-410397-AAA, R-64766, R064766) – atypical antipsychotic / monoamine receptor modulator
* Secretin (SecreFlo; INN-329, RG-1068) – hormone/diagnostic agent
* Sosei Heptares research programme – various mechanisms of action

## Not under development
### Development discontinued

* Bitopertin (R-1678, RG-6718, RG1678, RO-4917838) – glycine GlyT1 inhibitors / glycine reuptake inhibitor
* Cycloserine (D-cycloserine; TIK-101) – glutamate NMDA receptor partial agonist
* Elzasonan (CP-448187, CP-448187-01) – serotonin 5-HT$_{1B}$ and 5-HT$_{1D}$ receptor antagonist
* F-14258 – serotonin 5-HT$_{1B}$ and 5-HT$_{1D}$ receptor antagonist
* Fluoxetine/naltrexone (OREX-004) – selective serotonin reuptake inhibitor and opioid receptor antagonist
* Mavoglurant (AFQ-056) – glutamate mGlu5 receptor antagonist
* NPL-2003 – glutamate modulator
* Ondansetron (Setrodon; TO-2061) – serotonin 5-HT$_3$ receptor antagonist
* RO-600175 – serotonin 5-HT$_{2C}$ receptor agonist
* Roxindole (EMD-49980) – dopamine receptor agonist, serotonin receptor modulator, adrenergic receptor modulator, and serotonin reuptake inhibitor
* SB-200646 (SB-200646A) – serotonin 5-HT$_{2B}$ and 5-HT$_{2C}$ receptor antagonist

### Formal development never or not yet started

* 5-HT$_6$ receptor agonists (e.g., WAY-181187, WAY-208466)
* Antiandrogens (e.g., flutamide, cyproterone acetate, triptorelin)
* Cannabinoids (e.g., nabilone, tetrahydrocannabinol (THC)/cannabis) – cannabinoid receptor modulators
* NMDA receptor modulators (e.g., ketamine, memantine, nitrous oxide, rapastinel)
* Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., celecoxib, naproxen) – cyclooxygenase inhibitors
* Rituximab (Rituxan) – monoclonal antibody against CD20
* Serotonergic psychedelics (e.g., psilocybin/psilocybin mushrooms, lysergic acid diethylamide (LSD)) – serotonin receptor modulators
* Tolcapone (Tasmar) – catechol-O-methyltransferase inhibitor

## Clinically used drugs
### Approved drugs

* Clomipramine (Anafranil) – tricyclic antidepressant / monoamine reuptake inhibitor and receptor modulator
* Escitalopram (S-citalopram; Cipralex, Entact, Lexapro, Seroplex, Sipralex, Sipralexa; LU-26054; MLD-55) – selective serotonin reuptake inhibitor
* Fluoxetine (Prozac, Prozac Weekly, Reneuron, Sarafem; LY-110140) – selective serotonin reuptake inhibitor
* Fluvoxamine (Depromel, Luvox, Luvox CR; SME-3110) – selective serotonin reuptake inhibitor and sigma-1 receptor agonist
* Paroxetine (Aropax, Deroxat, Divarius, Dropax, Dropaxin, Frosinor, Motivan, Paxil, Paxil CR, Serestill, Seroxat, Tagonis; BRL-29060, BRL-29060A, FG-7051, NNC-207051, SI-211103) – selective serotonin reuptake inhibitor
* Sertraline (Aremis, Besitran, Gladem, J Zoloft, Lustral, Serad, Serlain, Tatig, Zoloft; CP-51974, CP-51974-01) – selective serotonin reuptake inhibitor

### Off-label drugs

* Atypical antipsychotics (e.g., aripiprazole, olanzapine, quetiapine, risperidone) – monoamine receptor modulators